Asset profile
BL-M07D1
Antibody–drug conjugate
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 12 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 59 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BL-M07D1: this drug | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | ||
| Zanidatamab | Approved | Multispecific antibody | HER2 | ||
| Zongertinib | Approved | Small molecule | HER2, HER2 Mutant-selective | ||
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Tucatinib | Phase 3 | Small molecule | HER2 | ||
| HRS-4508 | Phase 2 | Small molecule | HER2 | ||
| 177Lu-DWJ155 | Phase 1 | Radiopharmaceutical | HER2 | ||
| BL-M17D1 | Phase 1 | Antibody–drug conjugate | HER2 | ||
| KJ015 | Phase 1 | Monoclonal antibody | HER2 | ||
| MT-304 | Phase 1 | Cell therapy | HER2 | ||
| NVL-330 | Phase 1 | Small molecule | HER2 | ||
| DB-1303 | Phase 3 | Monoclonal antibody | HER2 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK |
…and 58 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (5)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (5)
December 2028 (5)
What to watch
What to watch
What to watch
What to watch
2029 (1)
December 2029 (1)
What to watch
2031 (1)
October 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.